Drugs Archives – Page 3 of 6 – Treatment Action Group

An Activist’s Guide to Rifapentine for the Treatment of TB Infection

April 30, 2020
Chad Cipiti

English version updated April 2020. The updated guide reflects new information from recently completed clinical trials, new WHO guidance on TB preventive therapy, and changes in rifapentine pricing and supply. Our publication, An Activist’s Guide to Rifapentine, details important efficacy,…

Science-Based Activism to End Epidemics, from AIDS to COVID-19

March 25, 2020
Dorrit Walsh

We hope you’re staying safe and sanitized during this difficult time! Here at TAG, we’re fortunate to be able to safely work from home, and advance the fight against HIV, tuberculosis, and hepatitis C — and now against COVID-19.

Isoniazid/Rifapentine (3HP) Access Roadmap and Patent Landscape

March 3, 2020
Dorrit Walsh

Our publication, Isoniazid/Rifapentine (3HP) Access Roadmap and Patent Landscape, provides a landscape of patent applications filed by the French pharmaceutical company Sanofi on combinations of two essential medicines used to prevent tuberculosis (TB): isoniazid and rifapentine.

Sanofi Withdraws Two Patent Applications on Life-Saving Tuberculosis Prevention Drugs in Europe and in Indonesia

January 22, 2020
Dorrit Walsh

Follow up to our 12/19 statement applauding Indian activists for taking legal action to oppose two patent applications filed by Sanofi in India. This joint statement from Treatment Action Group and OTMeds urges Sanofi to deliver on its promise to withdraw in all countries where the applications were filed and are still pending.

HIV & Aging

December 17, 2019
Chad Cipiti

A resource listing of articles, reports, websites, and ongoing clinical trials related to HIV and aging.

Clinical Trials for People with Suboptimal Immune Reconstitution Despite HIV Suppression

November 16, 2019
Chad Cipiti

Some individuals who initiate antiretroviral therapy (ART) experience limited recovery of CD4 T cell numbers despite suppression of HIV viral load to undetectable levels. The most common risk factors for this type of discordant response to ART are low CD4 T cell count at the time of starting and older age.

Protestors Demand Cepheid Halve the Price of GeneXpert TB Tests to US$5

October 31, 2019
Dorrit Walsh

The high cost of GeneXpert tests for tuberculosis (TB) leaves open a critical gap in the diagnosis of TB and fails to consider volume of sales and public investments in the development of GeneXpert.

A Lower Price for Rifapentine Is Just a Start – Communities Need More Than Discounts to Access TB Preventive Therapy

October 31, 2019
Dorrit Walsh

October 31, 2019 — Civil society and community-based organizations issued this letter welcoming the availability of lower-priced rifapentine, which is an essential medicine for preventing TB. However, while all the organizations agree that this discount is a step forward, they're…

Public Investments in TB Medicine Bedaquiline Far Exceed Those of Developer Johnson & Johnson

October 31, 2019
Dorrit Walsh

Presented at the 50th Union World Conference on Lung Health, an analysis by Treatment Action Group (TAG) finds that total public expenditures on the development of bedaquiline –– an important medicine for drug-resistant tuberculosis (DR-TB) –– far exceed those of the originator company, Johnson & Johnson.

A Lower Price for Rifapentine Is Just a Start – Communities Need More Than Discounts to Access TB Preventive Therapy

October 31, 2019
Dorrit Walsh

Civil society and community-based organizations issued this statement welcoming the availability of lower-priced rifapentine, which is an essential medicine for preventing TB.